- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT03718338
Mechanisms of Metabolic and Hormone Action on Plaque Formation in Brain and Carotid Vessels in Patients With Prostate Adenocarcinoma
Mechanisms of Metabolic and Hormone Action on Plaque Formation in Brain and Carotid Vessels in Men Undergoing Androgen Deprivation Therapy
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
OUTLINE:
Patients undergo clinical evaluations over 12 months including physical exam and vital signs, waist to hip circumference, medical history and events, laboratory evaluations, imaging evaluations, cognitive function evaluations, gait assessment, and quality of life questionnaires.
Type d'étude
Inscription (Réel)
Contacts et emplacements
Lieux d'étude
-
-
Washington
-
Seattle, Washington, États-Unis, 98109
- Fred Hutch/University of Washington
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Enfant
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
La description
Inclusion Criteria:
- Signed informed consent
- Histologically confirmed adenocarcinoma of the prostate
- Non-castrate disease with a serum testosterone level >= 50 ng/dL (1.73 nmol/L) at baseline
- No evidence of distant metastatic disease on baseline computed tomography-chest, abdomen and pelvis (CT-CAP) and bone scans
Patients will be stratified by the presence or absence of pre-existing cardiovascular disease defined as at least one of the following:
- Prior myocardial infarction >= 30 days before enrollment
Prior revascularization procedure >= 30 days before consent, including:
- Coronary artery stent placement or balloon angioplasty
- Coronary artery bypass graft surgery
- Stent placement or balloon angioplasty to a carotid, iliac, femoral, or popliteal artery
- Carotid endarterectomy surgery
- Vascular bypass surgery of the iliac, femoral, or popliteal artery
- Results from angiogram or CT angiogram of coronary, carotic, iliac, femoral, or popliteal arteries that documents at least one vascular stenosis >= 50% at any time point before enrollment
- Carotid ultrasound results that shows stenosis >= 50% at any time point before enrollment
- Ankle-brachial pressure index < 0.9 at any time point before enrollment
- Intent to initiate continuous androgen deprivation therapy (ADT) for at least 12 months
Exclusion Criteria:
- No prior treatment with ADT at time of study entry. (Prior neoadjuvant/adjuvant ADT is allowed only if the last injection of a depot formulation wore off at least 12 months prior to enrollment)
- Previous or concurrent hormonal or systemic therapy for prostate cancer including: anti-androgens, estrogens, megestrol acetate, ketoconazole, abiraterone, enzalutamide, or chemotherapy. (Prior or planned neoadjuvant bicalutamide for prevention of tumor flare is allowed)
- Plans to start or continue treatment with an investigational product after enrollment
- Poorly controlled type 1 or type 2 diabetes mellitus, based on hemoglobin A1c, as judged by the investigator
- Prior or planned surgical castration
- Poorly controlled hypertension at time of study entry, as judged by the investigator
- Myocardial infarction or stroke < 30 days prior to enrollment
- Coronary, carotid, or peripheral artery revascularization < 30 days prior to enrollment
- Planned or scheduled cardiac surgery or percutaneous coronary intervention (PCI) procedure that is known at the time of enrollment
- Mental incapacity or language barrier precluding adequate understanding or cooperation
- Inability to tolerate magnetic resonance imaging (MRI) imaging, or both Lupron and Degarelix
- Any other clinically significant disorder which may affect the subject's health or the outcome of the trial as judged by the investigator
- Estimated glomerular filtration rate (eGFR) < 45
- History of allergy to gadolinium contrast agent
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
Cohortes et interventions
Groupe / Cohorte |
Intervention / Traitement |
|---|---|
|
Clinical Evaluations
Patients undergo clinical evaluations over 12 months including physical exam and vital signs, waist to hip circumference, medical history and events, laboratory evaluations, imaging evaluations, cognitive function evaluations, gait assessment, and quality of life questionnaires.
|
Etudes annexes
Undergo clinical evaluations
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change in visual characterization of 18F-florbetapir (Amyvid) positron emission tomography (PET) scans results after Andorgen Deprivation Therapy
Délai: 12 Months
|
Change From Baseline visual characterization scan results at 12 months
|
12 Months
|
|
Change standardized uptake values of 18F-florbetapir (Amyvid) positron emission tomography (PET) scans results
Délai: 12 Months
|
Change from baseline standardized uptake values in select regions of interest at 12 months
|
12 Months
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Cognitive test results: Story recall
Délai: 12 months
|
Change in baseline Story Recall results at 12 months
|
12 months
|
|
Cognitive Test Results: Change in Montreal Cognitive Assessment (MOCA)
Délai: 12 Months
|
Change in baseline MOCA score results at 12 months
|
12 Months
|
|
Cognitive Test Results: Change in Clinical Dementia Rating Scale
Délai: 12 Months
|
Change in baseline Clinical Dementia Rating Scale score at 12 months
|
12 Months
|
|
Cognitive Test Results: Digit span
Délai: 12 Months
|
Change in baseline Digit span results at 12 months
|
12 Months
|
|
Cognitive Test Results: Letter number sequencing
Délai: 12 Months
|
Change in baseline Letter number sequencing results at 12 months
|
12 Months
|
|
Cognitive Test Results: Stroop Test Results
Délai: 12 Months
|
Change in baseline Stroop Test Results at 12 months
|
12 Months
|
|
Cognitive Test Results: Symbol Digit Modalities Test
Délai: 12 Months
|
Change in baseline Symbol Digit Modalities Test score at 12 months
|
12 Months
|
|
Cognitive Test Results: Visuo-Spatial Learning Test
Délai: 12 Months
|
Change in baseline Visuo-Spatial Learning Test results at 12 months
|
12 Months
|
|
Cognitive Test Results: Rey auditory verbal learning test (RVLT)
Délai: 12 Months
|
Change in baseline Rey auditory verbal learning test (RVLT) score at 12 months
|
12 Months
|
|
Inflammatory and immune markers: Change in CRP
Délai: 12 Months
|
Change in baseline CRP values at 12 months
|
12 Months
|
|
Inflammatory and immune markers: Change in IGFBP3
Délai: 12 Months
|
Change in baseline IGFBP3 at 12 months
|
12 Months
|
|
Inflammatory and immune markers: Change in IGFBP1
Délai: 12 Months
|
Change in baseline IGFBP1 at 12 months
|
12 Months
|
|
Inflammatory and immune markers: Change in IGF-1
Délai: 12 Months
|
Change in baseline IGF-1 at 12 months
|
12 Months
|
|
Inflammatory and immune markers: Change in IL-6
Délai: 12 Months
|
Change in baseline IL-6 at 12 months
|
12 Months
|
|
Metabolic Markers: Change in HgbA1C
Délai: 12 Months
|
Change in baseline HgbA1C at 12 months
|
12 Months
|
|
Metabolic Markers: Change in Estradiol
Délai: 12 Months
|
Change in baseline Estradiol at 12 months
|
12 Months
|
|
Metabolic Markers: Change in Follicle Stimulating Hormone (FSH)
Délai: 12 Months
|
Change in baseline Change in Follicle Stimulating Hormone (FSH) at 12 months
|
12 Months
|
|
Metabolic Markers: Change in Leptin
Délai: 12 Months
|
Change in baseline Leptin at 12 months
|
12 Months
|
|
Metabolic Markers: Change in Adiponectin
Délai: 12 Months
|
Change in baseline Adiponectin at 12 months
|
12 Months
|
|
Metabolic Markers: Change in homeostatic model assessment of insulin resistance (HOMA-IR)
Délai: 12 Months
|
Change in baseline HOMA-IR values at 12 months; Calculated based on fasting glucose and insulin test results.
|
12 Months
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Evan Yu, Fred Hutch/University of Washington Cancer Consortium
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- RG1001903
- 9939 (FHCRC)
- NCI-2018-01618 (Identificateur de registre: CTRP)
- 5P30CA015704 (Subvention/contrat des NIH des États-Unis)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .